Saved AI-generated translation. Medicine names, original references and image labels stay in their original language. The USA or UK edition stays the same.Traducción guardada generada por IA. Los nombres de medicamentos, las referencias originales y las etiquetas de las imágenes conservan su idioma original. Se mantiene la edición de EE. UU. o del Reino Unido.
La versión en español ya está guardada en este sitio. Al elegir Español no se envía el artículo a un servicio de traducción.
Generalised Anxiety Disorder (GAD)
Generalised anxiety disorder involves persistent, difficult-to-control worry across everyday situations, often with physical tension, sleep problems and fatigue.
Worry becomes a concern when it is hard to control, persists and interferes with everyday life. In generalised anxiety disorder, worries usually span several subjects, rather than one feared object or situation. Having real responsibilities or a stressful week does not by itself establish the disorder.
Signs and Symptoms
Alongside worry, people may feel restless, tense, easily tired or irritable. Sleep and concentration can suffer. Physical discomfort can be prominent. Symptoms may fluctuate with stress even when the underlying pattern lasts for months.
How Is It Diagnosed?
A GP asks about the worries, their duration and their effect on life. NHS information describes a pattern lasting at least six months; the assessment also considers physical symptoms and other explanations.
Assessment looks for difficult-to-control worry about multiple areas on most days for at least six months, together with associated symptoms and effects on functioning. A clinician reviews physical health, medicines and other possible explanations. The full assessment matters more than a symptom count alone.
NIMH reports a past-year estimate of 2.7% among US adults aged 18 or older in the 2001–2003 National Comorbidity Survey Replication. This older interview-based estimate describes that survey population and period; it is not a measurement of today's worldwide prevalence. These are not UK population estimates.
Causes and Risk Factors
Contributors may include family vulnerability, stressful experiences, painful long-term illness and substance use. Usually there is no single identifiable cause.
There is no single established cause. Family background, biology and environment can contribute. Stressful or traumatic experiences may raise risk, but a person does not need to identify one triggering event to seek care.
What Do We Know About the Brain?
Studies examine brain development and responses to threat alongside family and environmental influences. Research is also exploring why anxiety overlaps with other conditions. These findings do not reduce persistent worry to one brain region or one chemical.
What Else Can Look Similar?
Panic disorder, social anxiety and phobias involve different patterns of fear. Other mental or physical conditions and substance effects may also explain anxiety. A sudden or severe new physical symptom should not simply be assumed to be GAD.
Conditions That Can Occur Together
Depression and other anxiety disorders may occur alongside GAD. Sleep difficulties can add to the burden. An assessment should separate a second condition from symptoms that belong to the anxiety itself.
Treatment and Support
Treatment may involve supported self-help, cognitive behavioural therapy or applied relaxation. NICE uses stepped care, increasing support when symptoms and impairment require it. England’s NHS Talking Therapies accepts eligible self-referrals; access elsewhere follows local pathways.
NICE implementation and access differ across the four UK nations.
Cognitive behavioural therapy helps people understand patterns of worry and practice different responses. The NHS describes individual or group talking therapy, medication and specialist support when needed. Treatment choices depend on the person's needs and response.
For children and young people, treatment should fit their age and the cause of anxiety. CBT or counselling can help; severe anxiety or difficulties that persist despite therapy may need a child mental health specialist to consider medicine. Adult stepped-care and prescribing recommendations should not be applied automatically.
In Scotland, The Matrix describes child and parent-involved CBT in individual, group and supported digital formats, chosen according to severity and need. This is evidence about particular interventions and populations; local availability should be checked with the service.
Can Medication Help?
SSRIs are commonly considered when medicine is chosen. NICE advises against benzodiazepines for GAD apart from short-term crisis use. Benefits, side effectsAn effect beyond the intended treatment effectAn effect of a treatment in addition to its intended effect. It may be unwanted, harmful or sometimes beneficial.Read the full definition of Side effect and withdrawalWithdrawalSymptoms that may occur after reducing or stopping a medicine or substance to which the body has adapted.Read the full definition of Withdrawal risks need discussion.
Some antidepressants are used for GAD even when the person is not depressed. Benefits develop over time, and unwanted effects need review. Drug choice, approval and age limits differ by product; sharing a medication category does not make medicines interchangeable.
What to Expect Over Time
Symptoms can improve with treatment, though progress may take time and setbacks can occur. Follow-up helps identify what is working and whether the plan needs to change. Persistent symptoms deserve reassessment rather than blame.
Everyday Life and Support
Reducing excessive caffeine, regular activity and sleep support may help. Avoiding every feared situation can restrict life and is worth discussing in therapy.
Regular routines, enough sleep, physical activity and support from others may help. Notice whether caffeine or other substances worsen anxiety. These steps can accompany professional care; they do not require someone to solve persistent anxiety alone.
When to Seek Urgent Help
Seek urgent help if distress becomes a crisis. Severe or persistent chest pain or severe breathing difficulty requires emergency medical help now; do not assume it is anxiety. Other new or worsening physical symptoms need medical assessment.
History
NICE’s combined GAD and panic guideline was published in 2011. Its separate treatment pathways reflect the difference between persistent widespread worry and recurrent panic attacks.
The definition of generalised anxiety disorder has been refined as diagnostic systems have separated different patterns of fear and worry. A SAMHSA account of the transition from DSM-IV to DSM-5 describes relatively few changes to the core GAD criteria. Persistent worry across several areas and difficulty controlling it remained central.
One revision clarified that the symptoms should not be better explained by another mental disorder, instead of relying on a narrower list of exclusions. This history matters because generalised worry is not the same pattern as fear of a particular situation or repeated unexpected panic attacks.
Current assessment asks what the anxiety is about, how long it has lasted and how it affects life, rather than treating every anxious feeling as one diagnosisDiagnosisA clinical conclusion about the condition that best explains a person’s symptoms and other findings.Read the full definition of Diagnosis.
NHS England classifications browser · Accessed 2026-10-17
Scope: England coding reference.
Article Information
Edition
United Kingdom
Content updated
2026-10-30
Sources checked
Listed with each reference above; retained dates for shared scientific content.
Publication status
Published
Scope
Full condition-level educational explanation after individual comparison of all original article section roles, retaining verified UK assessment, care and medicine context. This is not a comprehensive specialist protocol, personalised advice or a claim of identical services across the UK.
Source and coverage limits
NICE recommendation passages were checked through official indexed text where direct retrieval returned HTTP 403.
Historical US statistics and global estimates remain geographically labelled; they are not substituted for UK prevalence.
No FDA product indication, dosing instruction or US medication example is imported. Product licences and detailed prescribing information require the independently verified UK medicine record.
NICE recommendations retain their stated age and topic scope. England-specific service names do not imply uniform pathways in Scotland, Wales or Northern Ireland.